Abstract 5172
Background
The aim of the present study was to investigate predictors of survival in a cohort of patients with incurable cancer. This may highlight areas of care which can be addressed to optimise outcomes.
Methods
Patient demographics, performance status (ECOG), inflammatory markers (modified Glasgow Performance Score (mGPS)), and nutritional parameters [BMI, % weight loss (WL)] were recorded. Baseline body composition were examined using computed tomography (CT) images. Sarcopenia and low muscle attenuation (MA) were defined using published cut-offs. Cancer cachexia (CC) was defined using the consensus definition (2011). Cox models were used to estimate mortality hazard ratios, adjusted for known prognostic covariates – age, sex & site.
Results
In total, 1027 patients were recruited (51% male, median age 66 years). Gastrointestinal cancer was most common (40%) and metastatic disease was present in 87% of patients. In total, 86% were on active chemotherapy treatment. On multivariate analysis, primary site, ECOG-PS, WL and mGPS predicted survival. Lung and GI cancer patients had higher risk of death compared to other tumour groups [HR:1.769 (95% CI:1.305–2.398), p < 0.001 and HR:1.576 (95% CI:1.211–2.053), p = 0.001, respectively]. mGPS score of 1 or 2 were associated with increased risk of death versus mGPS of 0 [HR:1.399 (95% CI:1.024–1.910), p = 0.035 & HR:1.831 (95% CI:1.442–2.324), p < 0.001, respectively]. WL > 10% in the preceding 3 months was associated with reduced survival [HR:2.501 (95% CI:1.425–4.389), p = 0.001]. Sarcopenia, CC and low MA were significant predictors of survival on univariate analysis, but not on multivariate analysis.
Conclusions
Independent predictors of survival in this cohort of advanced cancer patients were cancer site, ECOG, WL > 10% and mGPS, the latter two being important components of the cancer cachexia syndrome. Attenuation of weight loss and inflammation may improve outcomes for patients undergoing palliative treatment for cancer.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract